What is Cureline Clinical Consulting Partners?
Cureline Clinical Consulting Partners operates as a premier global precision and translational medicine contract research organization. Since its inception in 2003, the firm has specialized in biobanking and the procurement of human biospecimens, serving as a vital partner for biopharmaceutical entities. Their service portfolio is comprehensive, encompassing complex research protocol implementation, molecular and cellular analysis, and advanced translational histology. By focusing on high-impact therapeutic areas such as oncology, infectious diseases, and metabolic conditions, the company provides the essential infrastructure required for biomarker discovery and the development of companion diagnostics. Their expertise in tissue research and digital pathology positions them as a cornerstone for modern drug R&D initiatives.
How much funding has Cureline Clinical Consulting Partners raised?
Cureline Clinical Consulting Partners has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Cureline Clinical Consulting Partners
PPP
Public-Private Partnership
What's next for Cureline Clinical Consulting Partners?
With the recent influx of capital, Cureline is poised to scale its laboratory operations and enhance its digital pathology infrastructure. The strategic roadmap likely involves deepening its investment in molecular assay development and expanding its global network for biospecimen validation. As the industry shifts toward more personalized therapeutic interventions, the company's ability to provide high-quality, validated human tissue data will be a primary driver of its future growth. This late-stage funding context suggests a transition toward operational optimization and the potential for broader market penetration in the diagnostic development sector, ensuring the firm remains at the forefront of translational science.
See full Cureline Clinical Consulting Partners company page
